As Ozempic, Wegovy, Mounjaro and other injectable diabetes and weight-loss medications continue to make headlines for the successes and challenges many see with the medications for obesity and metabolic conditions, questions — regarding impacts on pregnant persons, potential uses for other medical conditions, concerns over counterfeit products that have flooded the market, discussions over what these mean for those with histories of disordered eating and more — continue to emerge.
On Monday, March 18, 2024, experts from the University of Maryland, Baltimore (UMB) met with members of the press for a virtual press briefing to discuss these topics and more. UMB’s renowned experts from its Schools of Medicine, Pharmacy, and Social Work provided important updates and insights on various aspects of these medications and their impact on patients.This panel discussion includes:• Experts from University of Maryland Baltimore discuss various medications and their effects• Discussion on the limitations of previous weight loss medications and their side effects• Explanation of how GLP-1 agonists work to control blood glucose levels and decrease hunger• Emphasis on the importance of treating obesity as a chronic disease and the benefits of doing so
More from Youtube
- 0:56Could Weight-Loss Drugs Curb Cravings for Addictive Substances? | Breakthroughs Can’t WaitEveryone has heard of Ozempic and Wegovy for treating diabetes and weight loss. But, what's been discovered in clinical trials, is an anti-craving effect is showing promising results for those battling alcohol and drug addiction.At the University of Maryland, Baltimore, researchers are exploring how GLP-1 receptor agonists — a class of drugs commonly used for weight loss — may offer new hope for people with cocaine use disorder. This is just one example of how federally funded research at UMB is Changing The Future Today.Hear from Sarah Kattakuzhy, MD, co-director for the Research Initiative on Infectious Disease and Substance Use Disorder, at the University of Maryland School of Medicine explains. Kattakuzhy is also the associate director of the Kahlert Institute for Addiction Medicine.🧪 Breakthroughs Can’t Wait: UMB research drives innovation, improves lives, and tackles global challenges. But we can’t do it without continued support.🔗 Learn more and support research that saves lives: https://www.umaryland.edu/breakthroughs #BreakthroughsCantWait #NIHfunding #CocaineUseDisorder #GLP1 #AddictionResearch #UMB #ResearchMatters
- 0:55Confronting the 4th Wave of the Drug Overdose Death Crisis | Breakthroughs Can't WaitOpioid and cocaine use epidemic is entrenched within Baltimore city, and there are no FDA-approved treatment for any stimulant disorders.At the University of Maryland, Baltimore, researchers are exploring how GLP-1 receptor agonists — a class of drugs commonly used for weight loss — may offer new hope for people with cocaine use disorder. This is just one example of how federally funded research at UMB is Changing The Future Today.Hear from Sarah Kattakuzhy, MD, co-director for the Research Initiative on Infectious Disease and Substance Use Disorder, at the University of Maryland School of Medicine explains. Kattakuzhy is also the associate director of the Kahlert Institute for Addiction Medicine.🧪 Breakthroughs Can’t Wait: UMB research drives innovation, improves lives, and tackles global challenges. But we can’t do it without continued support.🔗 Learn more and support research that saves lives: https://www.umaryland.edu/breakthroughs #BreakthroughsCantWait #NIHfunding #CocaineUseDisorder #GLP1 #AddictionResearch #UMB #ResearchMatters
- 0:45Can a Weight-Loss Drug Help Treat Cocaine Addiction? | Breakthroughs Can’t WaitCan a weight-loss drug help treat cocaine addiction?At the University of Maryland, Baltimore, researchers are exploring how GLP-1 receptor agonists — a class of drugs commonly used for weight loss — may offer new hope for people with cocaine use disorder. This is just one example of how federally funded research at UMB is Changing The Future Today.Hear from Sarah Kattakuzhy, MD, co-director for the Research Initiative on Infectious Disease and Substance Use Disorder, at the University of Maryland School of Medicine explains. Kattakuzhy is also the associate director of the Kahlert Institute for Addiction Medicine.🧪 Breakthroughs Can’t Wait: UMB research drives innovation, improves lives, and tackles global challenges. But we can’t do it without continued support.🔗 Learn more and support research that saves lives: https://www.umaryland.edu/breakthroughs #BreakthroughsCantWait #NIHfunding #CocaineUseDisorder #GLP1 #AddictionResearch #UMB #ResearchMatters
- 4:53Changing the Future of Addiction Care | Breakthroughs Can’t Wait with Dr. Sarah KattakuzhyCan a class of drugs best known for treating diabetes and weight loss also help people struggling with cocaine use disorder?Dr. Sarah Kattakuzhy, an associate professor at the University of Maryland School of Medicine, is leading innovative research on GLP-1 receptor agonists — medications that may offer a new path forward in treating addiction.This NIH-funded research could transform how we understand and address substance use, giving people more options — and more hope.🧪 Breakthroughs Can’t Wait: UMB research drives innovation, improves lives, and tackles global challenges. But we can’t do it without continued support.🔗 Learn more and support research that saves lives: https://www.umaryland.edu/breakthroughs#BreakthroughsCantWait #AddictionResearch #CocaineUseDisorder #GLP1 #SubstanceUseDisorder #UMBResearch #NIHfunding #HealthInnovation #DrSarahKattakuzhy
- 4:24UMB's 13th Annual Interprofessional Education DayHosted by the University of Maryland Baltimore's Center for Interprofessional Education (CIPE) on April 2, IPE Day brought together more than 170 students from all seven UMB professional schools — including medicine, nursing, pharmacy, law, dentistry, physical therapy, social work, and the Graduate School — for a full afternoon of collaborative learning, simulation activities, and real-life insights into the power of team-based care.Read more: https://www.umaryland.edu/news/archived-news/april-2025/ipe-day-centers-on-listening-to-patients-and-peers.php
- 59:34Virtual Face to Face: The Challenges Facing Academic ResearchThe changes and challenges facing academic research and the University of Maryland, Baltimore's response was the topic of Virtual Face to Face on April 10 hosted by James Hughes, MBA, Chief Enterprise and Economic Development Officer and Senior Vice President. Hughes was joined by University of Maryland School of Medicine Professor and Executive Vice Dean Chris O’Donnell, PhD, and E. Albert Reece, MD, PhD, MBA, Director of the Center for Advanced Research Training and Innovation.
